Systematic review of perioperative and survival outcomes of liver resections with and without preoperative portal vein embolization for colorectal metastases

HPB (Oxford). 2017 Jul;19(7):559-566. doi: 10.1016/j.hpb.2017.03.003. Epub 2017 Apr 21.

Abstract

Background: The aim of this systematic review was to evaluate perioperative and long term outcomes in patients who underwent PVE prior to liver resection for colorectal liver metastases.

Methods: A systematic search of PubMed, MEDLINE, Embase and the Cochrane library was performed in accordance with PRISMA guidelines. Studies including patients who underwent liver resection with and without PVE (N-PVE) were included.

Results: Thirteen studies including 1345 were included of which 539 patients had PVE and 806 had N-PVE. Eight studies reported that from a total of 450 patients who underwent PVE, 136 (30%) did not proceed to liver resection. In 114 (84%) patients this was due to disease progression. The postoperative morbidity was 42% (n = 151) after PVE and 10% (n = 35) developed postoperative liver failure after liver resection. Median overall survival, reported in all studies, was 38.9 months and 45.6 months respectively, following resection with PVE and N-PVE. The median disease free survival, reported in eight studies, was 15.7 (PVE) and 21.4 (N-PVE) months respectively.

Conclusion: Following PVE 70% of patients proceed to liver resection, with a 10% risk of postoperative liver failure. Tumour progression after PVE was the predominant reason for not proceeding to liver resection.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / pathology*
  • Disease Progression
  • Disease-Free Survival
  • Embolization, Therapeutic / adverse effects
  • Embolization, Therapeutic / methods*
  • Embolization, Therapeutic / mortality
  • Hepatectomy* / adverse effects
  • Hepatectomy* / mortality
  • Humans
  • Liver Failure / etiology
  • Liver Neoplasms / mortality
  • Liver Neoplasms / secondary*
  • Liver Neoplasms / therapy*
  • Portal Vein*
  • Risk Factors
  • Time Factors
  • Treatment Outcome